Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) With Functional Constipation

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) With Functional Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AbbVie; Allergan

Most Recent Events

  • 01 Sep 2024 Results(n=34) evaluating the dose-response, safety, and efficacy of 4 weeks of linaclotide compared with placebo in children 2-5 years of age with functional constipation , published in the Journal of Pediatric Gastroenterology and Nutrition
  • 09 May 2022 According to an Ironwood Pharmaceuticals media release, data from this study will be presented at the Digestive Disease WeekCarlo Di Lorenzo, M.D., Nationwide Children's Hospital. (DDW) 2022 meeting by
  • 11 May 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top